The Journal of Urology
Volume 178, Issue 3 , Pages 849-853 , September 2007

Serum Bone Turnover Markers (PINP and ICTP) for the Early Detection of Bone Metastases in Patients With Prostate Cancer: A Longitudinal Approach

  • N. Koopmans

      Affiliations

    • Department of Urology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
    • Corresponding Author InformationCorrespondence: Department of Urology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30 001, 9700 RB, Groningen, the Netherlands (telephone: +31-50-3612380; FAX: +31-50-3619607).
    • ,
  • I.J. de Jong

      Affiliations

    • Department of Urology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
    • ,
  • A.J. Breeuwsma

      Affiliations

    • Department of Urology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
    • ,
  • E. van der Veer

      Affiliations

    • Department of Pathology and Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands

Received 29 January 2007

References 

  1. Rosenthal DI. Radiologic diagnosis of bone metastases. Cancer. 1997;80:1595
  2. Jung K, Lein M, Stephan C, Von HK, Semjonow A, Sinha P, et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer. 2004;111:783
  3. O’Sullivan JM, Cook GJ. A review of the efficacy of bone scanning in prostate and breast cancer. Q J Nucl Med. 2002;46:152
  4. Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer. 2000;82:858
  5. Koga H, Naito S, Koto S, Sakamoto N, Nakashima M, Yamasaki T, et al. Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer. Prostate. 1999;39:1
  6. Koizumi M, Yonese J, Fukui I, Ogata E. The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int. 2001;87:348
  7. Tamada T, Sone T, Tomomitsu T, Jo Y, Tanaka H, Fukunaga M. Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy. J Bone Miner Metab. 2001;19:45
  8. Kylmala T, Tammela TL, Risteli L, Risteli J, Kontturi M, Elomaa I. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer. 1995;71:1061
  9. Noguchi M, Noda S. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. J Urol. 2001;166:1106
  10. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000;163:181
  11. Miyaji Y, Saika T, Yamamoto Y, Kusaka N, Arata R, Ebara S, et al. Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer. Urology. 2004;64:128
  12. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154
  13. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90:6410
  14. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol. 1997;157:439
  15. Ramankulov A, Lein M, Kristiansen G, Loening SA, Jung K. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate. 2007;67:330
  16. Lein M, Wirth M, Miller K, Eickenberg HU, Weissbach L, Schmidt K, et al. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol. 2007;epub ahead of print.
  17. Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res. 2003;18:859
  18. Li BY, Liao XB, Fujito A, Thrasher JB, Shen FY, Xu PY. Dual androgen-response elements mediate androgen regulation of MMP-2 expression in prostate cancer cells. Asian J Androl. 2007;9:41
  19. Brasso K, Christensen IJ, Johansen JS, Teisner B, Garnero P, Price PA, et al. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate. 2006;66:503
  20. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879

 Nothing to disclose.Study received hospital ethical board approval.For another article on a related topic see page 1086.Editor’s Note: This article is the second of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 1128 and 1129.

PII: S0022-5347(07)01238-4

doi: 10.1016/j.juro.2007.05.029

The Journal of Urology
Volume 178, Issue 3 , Pages 849-853 , September 2007

Article Tools

* Image Usage & Resolution